
Yahoo · 15 de sept de 2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Se…
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Últimos 203 días · 12/11/25 — 14/09/26
+46.78%
Precio
$ 26.440
Var. %
-0,75%
Volumen operado
3.217
Precio BIIB
US$ 215,87
Teórico (precio / ratio)
BIIB ÷ 13
US$ 16,61
Sí, existe el CEDEAR de BIIB (Biogen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es BIIB.
El ticker del CEDEAR de Biogen Inc. en Argentina es BIIB. La acción subyacente cotiza en NASDAQ con el símbolo BIIB.
El CEDEAR BIIB tiene un ratio de 13:1. Eso significa que 13 CEDEARs equivalen a 1 acción de BIIB.
El CEDEAR BIIB cotiza hoy a $ 26.440 en pesos argentinos, con una variación diaria de -0,75%.
La acción subyacente BIIB (Biogen Inc.) cotiza a US$ 215,87 en su mercado de origen (NASDAQ).

Yahoo · 15 de sept de 2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Se…

Yahoo · 15 de sept de 2026
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chri…

SeekingAlpha · 14 de sept de 2026
Biogen Inc. (BIIB) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 9:15 AM EDTCompany ParticipantsChristopher Viehbacher -...
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 17,60
vs teórico
+5,99%
Cotización MEP implícita
$ 1.502,27
Cotización
—
vs teórico
—
Cotización Cable implícita
—
El precio teórico del CEDEAR BIIB se calcula dividiendo el precio de BIIB por el ratio (13). Hoy resulta en US$ 16,61.
En BYMA podés operar BIIB en pesos, BIIBD en dólar MEP y BIIBC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR BIIB en pesos argentinos, con datos de data912.

Yahoo · 12 de sept de 2026
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeli…

ChartMill · 10 de sept de 2026
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.
Benzinga · 10 de sept de 2026
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.

SeekingAlpha · 9 de sept de 2026
Biogen Inc. (BIIB) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 9:30 AM EDTCompany ParticipantsRobin Kramer - Executive VP & CFOAdam...

CNBC · 9 de sept de 2026
Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication an…
Noticias vía Finnhub